Did hypocretin receptor 2 autoantibodies cause narcolepsy with hypocretin deficiency in Pandemrix-vaccinated children, as suggested by Ahmed et al.? Using newly developed mouse models to report and inactivate hypocretin receptor expression, Vassalli et al. now show that hypocretin neurons (whose loss causes narcolepsy) do not express hypocretin autoreceptors, raising questions to the interpretation of Ahmed et al.'s findings.
Ahmed and colleagues (1) recently reported that "antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2." This important finding might explain why many cases of child narcolepsy were reported after immunization with the Adjuvant System 03 (ASO3)-adjuvanted A(H1N1)pdm09 influenza vaccine (Pandemrix) during the 2009 flu pandemia, mainly in Finland and Sweden where the highest rates of vaccination were achieved in Europe. Besides several concerns about the report of Ahmed and colleagues (1) [for example, 55% of control children were found positive for these autoantibodies as well, lack of availability of peripheral cells and cerebrospinal fluid (CSF), and no evidence of disease transfer in an animal model], a major unanswered question is how these anti-hypocretin receptor 2 (HCRTR2) antibodies may cause the disease. A direct antibodydependent cell-mediated cytotoxicity appears unlikely as this would result in a massive damage and detectable inflammatory signs because HCRTR2 is expressed in numerous brain cell types, including some with critical functions (such as histaminergic and serotonergic cell groups) (2) . A plausible hypothesis might be (if it is shown that these antibodies penetrate the brain) that, similar to myasthenia gravis, anti-HCRTR2 antibodies block and inhibit HCRTR2 function. Such process can lead to narcolepsy symptoms because spontaneous mutations in the Hcrtr2 gene are found to cause narcolepsy in dogs (3), and mice in which the Hcrtr2 gene was inactivated also present narcolepsy-like symptoms (4) . In humans, in contrast, both sporadic and, presumably, post-H1N1 cases of narcolepsy with cataplexy are caused by the specific loss of hypocretin (HCRT)-producing neurons. Postmortem examination of narcoleptic brains uncovered extensive loss of these neurons together with the colocalized dynorphin and narp (neuronal activityregulated pentraxin) neuropeptides in the lateral hypothalamus (5, 6) . Also, deficiency in HCRT-1 in the CSF allows specific diagnosis of narcolepsy (7) . One may hypothesize that HCRTR2 blockade by autoantibodies inhibits HCRT production (HCRT neurons are intact but they do not produce HCRT and colocalized neuropeptides), either by directly binding HCRT neurons or by binding other neurons regulating them. Binding and inhibition of HCRTR2 may thus occur in HCRT-producing neurons themselves. Indeed, Yamanaka and colleagues (8) used Hcrt gene promoter-driven enhanced green fluorescent protein (eGFP) transgenic mice and reported that hypocretin neurons are critically and directly controlled by HCRTR2, thus arguing that hypocretin neurons express HCRTR2 as autoreceptor. However, these transgenic mice are thought to lack specificity, so not all eGFP-immunoreactive neurons are HCRT-positive. Moreover, commercially available anti-HCRTR2 antibodies [as used in the study of Ahmed and colleagues (1)] lack reliability. HCRTR2 expression has thus been difficult to assess at single-cell type resolution, and whether HCRT neurons express HCRTR2 is controversial.
It is noteworthy that in both mouse and dog models of HCRTR2 deficiency, HCRT neurons show normal distribution and HCRT production, and brain HCRT levels appear normal [(4, 9), and Fig. 1E for the mouse model reported here]. Thus, the mechanism by which lesions in HCRTR2 lead to narcolepsy with hypocretin deficiency remains unclear.
We have generated mouse conditional knockout (KO) alleles for Hcrtr1 and Hcrtr2. Our conditional alleles are designed in a way that when Cre-mediated excision within the gene occurs, GFP replaces the endogenous protein encoding region (Fig. 1, A and B) and therefore can be used as a reliable reporter for mapping of cells in which these receptors are endogenously expressed (10) . By using GFP and HCRT double immunohistofluorescence, we found no HCRT/HCRTR2 doublelabeled neurons, strongly indicating that HCRT neurons lack HCRTR2 (Fig. 1E) . In contrast, our mouse model clearly reveals HCRTR2 expression in histaminergic neurons of the tuberomammillary nucleus (Fig. 1C) . Nevertheless, many other hypothalamic (Fig. 1E ) and extrahypothalamic cells are GFP-positive. The identity of many of these HCRTR2 neurons is unknown, and whether they project to and eventually activate (or in any manner affect the activity of) HCRT neurons needs further studies. We found that most hypocretin neurons (302 of 316) also do not express HCRTR1 (Fig. 1F ). In conclusion, HCRT deficiency in narcolepsy is most probably due to a specific destruction of HCRT-producing neurons, and although the mechanism (presumably autoimmune attack) remains unknown, there is no evidence that this includes antibodies against HCRTR2. Therefore, until the pathogenicity of the reported anti-HCRTR2 antibodies is established, the findings of Ahmed and colleagues (1) should be considered as preliminary and not as evidence for molecular mimicry between H1N1 nuclear protein and HCRTR2, resulting in hypocretin deficiency. conditional KO allele, and Hcrtr2 tm1.2Ava (MGI:5637403) for the D-GFP KO allele] will be described in further details elsewhere. Figure 1 (C and E) depict the brain of a mouse heterozygous (C), and homozygous (E) for the Hcrtr2 D-GFP allele. The cell distribution pattern seen in the homozygous mouse shown in (E) was also observed in four animals heterozygous for this mutation (thus carrying a WT functional Hcrtr2 allele). Figure 1D shows the brain of a mouse homozygous for the Hcrtr1 floxed allele and carrying a Dbh-Cre transgene. Figure 1F depicts the hypothalamus of a mouse heterozygous for Hcrtr1 
